DS Stage II Plasma Cell Myeloma Active Not Recruiting Phase 1 / 2 Trials for Elotuzumab (DB06317)

IndicationStatusPhase
DBCOND0030429 (DS Stage II Plasma Cell Myeloma)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01668719S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple MyelomaTreatment